Eye pressure check after Eylea 8mg injection
Part of Eyes & vision clinical trials.
This trial measures eye pressure right after an injection of a higher-dose Eylea (aflibercept 8mg) to see how it affects the eye. It may help people who need frequent anti-VEGF shots for conditions like wet AMD or diabetic eye disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your doctor has prescribed Eylea 8mg for your eye condition
- You are either starting Eylea for the first time or switching from another anti-VEGF treatment because you are not responding well enough
- You have health insurance (social security coverage)
- You are not pregnant or breastfeeding
- You are not under legal guardianship or similar protection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how eye pressure changes right after an eye injection. It aims to help doctors better understand and manage pressure spikes after treatment.
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
Hear when a new Macular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.